home / stock / arwr / arwr news


ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 01/21/22

Stock Information

Company Name: Arrowhead Pharmaceuticals Inc.
Stock Symbol: ARWR
Market: NASDAQ
Website: arrowheadpharma.com

Menu

ARWR ARWR Quote ARWR Short ARWR News ARWR Articles ARWR Message Board
Get ARWR Alerts

News, Short Squeeze, Breakout and More Instantly...

ARWR - Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 2, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 first quarter ended December 31, 2021. Conference Call and Webcast Details ...

ARWR - Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the PALISADE study, a Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS). ARO-APOC3 is the company’s i...

ARWR - Meta hits UBS list of most crowded trades, most megacaps still uncrowded: At the Open

UBS updates its list of most crowded and least crowded trades for December. "Essentially, we sum up all of the holdings in dollar value across all of the active managers and calculate the weights of stocks in this active trading portfolio," UBS' global team of analysts writes. "We then compar...

ARWR - Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI, which is planned to be the site of an approximately 140,000 square foot drug manufacturing facility and an approxi...

ARWR - Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity

BEAM's novel CRISPR technology gives it a niche in a crowded and volatile market alongside other CRISPR companies trading at high valuations. While the 'standard' CRISPR-cas9 approach cuts double-stranded DNA and to insert genetic sequences, base editing erases a point mutation and re...

ARWR - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 14, 2021, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 24 new employees u...

ARWR - Direxion Launches mRNA ETF (MSGR)

Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...

ARWR - My 29-Stock $410k November Portfolio Is Ready For The Santa Claus Rally

My portfolio, built specifically for my retirement ~20+ years from now, rides the November volatility in the market as this year's Santa run begins amidst COVID fears. Rivian finally IPOs as I add shares of this EV monster to hopefully follow in the footsteps of Tesla as America's aut...

ARWR - Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 4th Annual Evercore ISI HealthCONx Conference December 2, 2021, 1:00 p.m. ET – Chris Anzalone, Ph.D., Arrowhead’s president a...

ARWR - 4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

Danish pharmaceutical giant, Novo Nordisk (NYSE: NVO) made a lot of headlines recently with a big buyout offer for Dicerna Pharmaceuticals (NASDAQ: DRNA) . Novo Nordisk offered Dicerna shareholders a great big 80% premium , leading investors to wonder which biotech stock...

Previous 10 Next 10